These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 18565963

  • 1. Is salmeterol/fluticasone propionate equivalent to tiotropium bromide in the treatment of COPD?
    Gillissen A.
    Am J Respir Crit Care Med; 2008 Jul 01; 178(1):105; author reply 106-7. PubMed ID: 18565963
    [No Abstract] [Full Text] [Related]

  • 2. Treatment step down should be avoided at entry in COPD therapeutic trials.
    Marchand E.
    Am J Respir Crit Care Med; 2008 Jul 01; 178(1):105-6; author reply 106-7. PubMed ID: 18565962
    [No Abstract] [Full Text] [Related]

  • 3. Do we need three players in COPD treatment?
    Maestrelli P, Mason P, Costa F, Paggiaro P.
    Respiration; 2013 Jul 01; 86(4):275-6. PubMed ID: 23988429
    [No Abstract] [Full Text] [Related]

  • 4. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.
    Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, Bishop G, Anthony J, Cowie R, Field S, Hirsch A, Hernandez P, Rivington R, Road J, Hoffstein V, Hodder R, Marciniuk D, McCormack D, Fox G, Cox G, Prins HB, Ford G, Bleskie D, Doucette S, Mayers I, Chapman K, Zamel N, FitzGerald M, Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium.
    Ann Intern Med; 2007 Apr 17; 146(8):545-55. PubMed ID: 17310045
    [Abstract] [Full Text] [Related]

  • 5. Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease.
    Hoshino M, Ohtawa J.
    Respirology; 2011 Jan 17; 16(1):95-101. PubMed ID: 20920142
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Impact of adherence to treatment with tiotropium and fluticasone propionate/salmeterol in chronic obstructive pulmonary diseases patients.
    Ismaila A, Corriveau D, Vaillancourt J, Parsons D, Dalal A, Su Z, Sampalis JS.
    Curr Med Res Opin; 2014 Jul 17; 30(7):1427-36. PubMed ID: 24666181
    [Abstract] [Full Text] [Related]

  • 8. The INSPIRE trial results: are they truly breathtaking?
    Chui D, Tejani AM.
    Am J Respir Crit Care Med; 2009 Jan 01; 179(1):80; author reply 80-1. PubMed ID: 19098157
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Tiotropium versus salmeterol in COPD.
    Lloret-Linares C, Bergmann JF.
    N Engl J Med; 2011 Jun 30; 364(26):2552-3; author reply 2553-4. PubMed ID: 21714656
    [No Abstract] [Full Text] [Related]

  • 12. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study.
    Jung KS, Park HY, Park SY, Kim SK, Kim YK, Shim JJ, Moon HS, Lee KH, Yoo JH, Lee SD, Korean Academy of Tuberculosis and Respiratory Diseases study group, Korea Chronic Obstructive Pulmonary Disease study group.
    Respir Med; 2012 Mar 30; 106(3):382-9. PubMed ID: 21975275
    [Abstract] [Full Text] [Related]

  • 13. Tiotropium versus salmeterol in COPD.
    Schembri S.
    N Engl J Med; 2011 Jun 30; 364(26):2553; author reply 2553-4. PubMed ID: 21714655
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone.
    Kurashima K, Hara K, Yoneda K, Kanauchi T, Kagiyama N, Tokunaga D, Takayanagi N, Ubukata M, Sugita Y.
    Respirology; 2009 Mar 30; 14(2):239-44. PubMed ID: 19210650
    [Abstract] [Full Text] [Related]

  • 16. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD.
    Cazzola M, Andò F, Santus P, Ruggeri P, Di Marco F, Sanduzzi A, D'Amato M.
    Pulm Pharmacol Ther; 2007 Mar 30; 20(5):556-61. PubMed ID: 16914336
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD.
    Hanania NA, Crater GD, Morris AN, Emmett AH, O'Dell DM, Niewoehner DE.
    Respir Med; 2012 Jan 30; 106(1):91-101. PubMed ID: 22040533
    [Abstract] [Full Text] [Related]

  • 20. TORCH and UPLIFT: what has been learned from the COPD "mega-trials"?
    Niewoehner DE.
    COPD; 2009 Feb 30; 6(1):1-3. PubMed ID: 19229702
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.